Table 1.
Demographic data and PV B19 serostatus of the disease subgroups and the corresponding age-related control subgroups
| Classification | Disease subgroupsa | Age-matched control groups | ||||||||||
| n | Female (%) | Mean age (years)b | Age range (years)b | B19 IgG+ (n [%]) | Pc | Subgroup | n | Female (%) | Mean age (years)b | Age range (years)b | B19 IgG+ (n [%]) | |
| EOPA | 67 | 76.1 | 4.5 | 1.3–15.0 | 21 (31.3) | <0.05 | 1 | 36 | 38.9 | 5.5 | 0.8–9.3 | 17 (47.2) |
| Systemic arthritis (Still's disease) | 8 | 100 | 6.7 | 4.8–11.1 | 5 (62.5) | NS | ||||||
| Eye disease, rheumatoid (iridocyclitis) | 6 | 83.3 | 7.3 | 3.8–11.1 | 2 (33.3) | NS | ||||||
| Reactive arthritis | 38 | 31.6 | 7.5 | 1.8–16.2 | 15 (39.5) | <0.05 | 2 | 30 | 50.0 | 8.9 | 1.5–15.8 | 19 (63.3) |
| Other arthritis (unclassified) | 28 | 50 | 8.8 | 1.0–15.1 | 16 (57.1) | NS | ||||||
| Arthralgias | 85 | 48.2 | 9.3 | 2.3–16.5 | 53 (62.4) | NS | ||||||
| Polyarthritis (RF+ and RF-) | 19 | 78.9 | 9.7 | 2.6–15.7 | 11 (57.9) | NS | ||||||
| Lyme arthritis | 37 | 43.2 | 10.2 | 2.8–15.5 | 25 (67.6) | NS | 3 | 80 | 41.3 | 11.2 | 1.9–18.3 | 52 (65.0) |
| Other oligoarthritis (non-EOPA JIA) | 13 | 38.5 | 10.6 | 4.8–18.8 | 7 (53.9) | NS | ||||||
| Psoriatic arthritis | 11 | 63.6 | 10.7 | 1.3–15.0 | 7 (63.6) | NS | ||||||
| CRMO | 12 | 66.7 | 11.5 | 6.8–15.3 | 6 (50.0) | NS | ||||||
| EAA | 54 | 61.1 | 11.6 | 1.9–18.3 | 39 (72.2) | NS | ||||||
| SLE | 4 | 100 | 13.0 | 9.7–15.9 | 4 (100) | NS | ||||||
aSubgroups ordered by mean age. bAge when serum sample used for parvovirus (PV) B19 testing was drawn. cComparison of disease subgroup with age-matched control group. CRMO, Chronic recurrent multifocal osteomyelitis; EAA, Enthesitis associated arthritis; EOPA, Early-onset pauciarticular arthritis; JIA, juvenile idiopathic arthritis; NS, not significant; RF, rheumatoid factor; SLE, System ic lupus erythematosus.